Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07724626) titled 'Hyperpolarized MRI for GIST on Imatinib' on July 21.

Study Type: Observational

Primary Sponsor: Chang Gung Memorial Hospital

Condition: Imatinib Therapy Response Gastrointestinal Stromal Tumor (GIST)

Intervention: Drug: Hyperpolarized 13C-MRI

Recruitment Status: Not recruiting

Date of First Enrollment: January 1, 2027

Target Sample Size: 30

Countries of Recruitment: Taiwan

To know more, visit https://clinicaltrials.gov/study/NCT07724626

Disclaimer: Curated by HT Syndication....